Want to see HK:2159 full AI Analyst Report?
2159 Stock Chart & Stats
HK$1.24
HK$0.00(0.00%)
At close: 4:00 PM EST
HK$1.24
HK$0.00(0.00%)
Day’s Range― - ―
52-Week RangeHK$1.06 - HK$2.27
Previous CloseN/A
Volume32.00K
Average Volume (3M)143.19K
Market Cap
HK$428.40M
Enterprise ValueHK$322.49M
Total Cash (Recent Filing)HK$99.36M
Total Debt (Recent Filing)HK$54.49M
Price to Earnings (P/E)45.8
Beta0.55
Next Earnings
Sep 02, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.03
Shares Outstanding280,000,000
10 Day Avg. Volume118,880
30 Day Avg. Volume143,186
Financial Highlights & Ratios
PEG Ratio-0.20
Price to Book (P/B)2.15
Price to Sales (P/S)0.51
P/FCF Ratio96.86
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue Growth ReboundA 48.05% revenue rebound in 2025 shows the company can regain top-line momentum after prior weakness. Durable revenue recovery increases scale, improves fixed-cost absorption, and provides a larger base to fund product development and commercial investment if growth persists across quarters.
Return To Net ProfitabilityAchieving a positive net margin (2.13%) in 2025 demonstrates the business can generate bottom-line profits under current operations. Sustained net profitability reduces reliance on external funding, enables reinvestment, and is a structural step toward durable free cash flow generation if margins remain positive.
Improved Leverage ProfileDebt-to-equity improved to 0.49 from 0.67, indicating a stronger balance-sheet position. Lower leverage reduces refinancing risk and interest burden, supporting financial flexibility and the capacity to fund organic growth or sustain operations through cyclical periods without immediate external capital.
Bears Say
Very Thin Operating MarginOperating margin of 0.39% leaves almost no buffer for cost shocks, pricing pressure, or investment needs. Near-break-even operating profitability limits the company's ability to self-fund growth, compresses cushion for margin recovery, and increases sensitivity to adverse demand or cost swings long term.
Unstable Cash GenerationFree cash flow plunged 76% year-over-year and the company had several years of negative operating cash flow through 2024. Weak, inconsistent cash conversion constrains capital allocation, raises refinancing needs, and makes sustained investment or dividend capacity uncertain without continued improvement.
Earnings Volatility And Modest ROEHistoric swings from profits to deep losses through 2022–2024 and only modest ROE of 8.74% in 2025 indicate uneven capital productivity. Persistent earnings volatility undermines predictability for investors and may signal structural execution risks that hamper long-term return generation.
Mediwelcome Healthcare Management & Technology Inc. News
2159 FAQ
What was Mediwelcome Healthcare Management & Technology Inc.’s price range in the past 12 months?
Mediwelcome Healthcare Management & Technology Inc. lowest stock price was HK$1.06 and its highest was HK$2.27 in the past 12 months.
What is Mediwelcome Healthcare Management & Technology Inc.’s market cap?
Mediwelcome Healthcare Management & Technology Inc.’s market cap is HK$428.40M.
When is Mediwelcome Healthcare Management & Technology Inc.’s upcoming earnings report date?
Mediwelcome Healthcare Management & Technology Inc.’s upcoming earnings report date is Sep 02, 2026 which is in 46 days.
How were Mediwelcome Healthcare Management & Technology Inc.’s earnings last quarter?
Mediwelcome Healthcare Management & Technology Inc. released its earnings results on Mar 23, 2026. The company reported HK$0.083 earnings per share for the quarter, beating the consensus estimate of N/A by HK$0.083.
Is Mediwelcome Healthcare Management & Technology Inc. overvalued?
According to Wall Street analysts Mediwelcome Healthcare Management & Technology Inc.’s price is currently Overvalued.
Does Mediwelcome Healthcare Management & Technology Inc. pay dividends?
Mediwelcome Healthcare Management & Technology Inc. does not currently pay dividends.
What is Mediwelcome Healthcare Management & Technology Inc.’s EPS estimate?
Mediwelcome Healthcare Management & Technology Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Mediwelcome Healthcare Management & Technology Inc. have?
Mediwelcome Healthcare Management & Technology Inc. has 280,000,000 shares outstanding.
What happened to Mediwelcome Healthcare Management & Technology Inc.’s price movement after its last earnings report?
Mediwelcome Healthcare Management & Technology Inc. reported an EPS of HK$0.083 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -0.526%.
Which hedge fund is a major shareholder of Mediwelcome Healthcare Management & Technology Inc.?
Currently, no hedge funds are holding shares in HK:2159
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Mediwelcome Healthcare Management & Technology Inc. Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
116.98%
12-Months-Change
Fundamentals
Return on Equity
11.38%
Trailing 12-Months
Asset Growth
2.72%
Trailing 12-Months
Company Description
Mediwelcome Healthcare Management & Technology Inc.
As an investment holding entity, Mediwelcome Healthcare Management & Technology Inc. delivers comprehensive marketing solutions for the healthcare sector within the People's Republic of China. Its service portfolio encompasses medical conference organization, patient education and screening programs, along with strategic marketing and advisory support. Additionally, the company provides Contract Research Organization (CRO) services, specifically focusing on patient recruitment and clinical data gathering. Furthermore, Mediwelcome manages a mobile application that facilitates internet hospital functionalities, including virtual follow-up consultations for physicians' current patients and electronic prescription services. Its diverse client base includes pharmaceutical firms, medical associations, and various foundations. Established in 2000, Mediwelcome Healthcare Management & Technology Inc. maintains its headquarters in Beijing, China.
Mediwelcome Healthcare Management & Technology Inc. (2159) Earnings & Revenues
Technical Analysis
Honliv Healthcare Management Group Co Ltd
―
Perfect Medical Health Management Limited
―
EC Healthcare
―
Yidu Tech, Inc.
―
Town Health International Medical Group Ltd.
―